Search results
23 sie 2020 · Through the NCTAP, Medicare provided an enhanced payment through September 30, 2023, for eligible inpatient cases that used certain new products with current FDA approval or emergency use authorization (EUA) to treat COVID-19, including the following:
- COVID-19 Monoclonal Antibodies
Medicare Payment for Administering COVID-19 Monoclonal...
- COVID-19 Monoclonal Antibodies
Medicare Payment for Administering COVID-19 Monoclonal Antibody Products. To ensure immediate access during the COVID-19 PHE, Medicare covers and pays for these infusions and injections in accordance with Section 3713 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act).
7 wrz 2021 · Supportive care for moderate/severe COVID-19 cost $11,112.98 with 0.7155 quality adjusted life-year (QALY) obtained. Using dexamethasone for all patients was the most-cost effective with an...
14 lip 2020 · The direct cost impact of remdesivir for Medicare, at least in the short term, is limited to spending under traditional Medicare, which covers two-thirds of Medicare beneficiaries.
We have set the government price of remdesivir at $390 per vial or $2,340 per 5-day treatment course in developed countries. In the United States, we have also set a list price for commercial insurers of $520 per vial or $3,120 per 5-day treatment course.
19 lut 2022 · This study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of hospitalized patients with COVID-19, and identify key drivers of value to guide future pricing and reimbursement efforts.
12 paź 2022 · Cost estimates for remdesivir ranged widely, from $10 to $780 for a 10-day course. In three out of four included economic evaluations, remdesivir treatment scenarios were cost-effective, ranging from ~ 8 to ~ 23% of the willingness-to-pay threshold for the respective country.
